Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.

Xu Y, Zhang C, Chen D, Zhao J, Shen Z, Wu Y, Zhu Y.

Tumour Biol. 2013 Dec;34(6):4065-71. doi: 10.1007/s13277-013-0996-4. Epub 2013 Jul 20. Erratum in: Tumour Biol. 2013 Dec;34(6):4101.

PMID:
23873112
2.

The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.

Xu Y, Zhu Q, Chen D, Shen Z, Wang W, Ning G, Zhu Y.

Tumour Biol. 2015 Jul;36(7):5103-8. doi: 10.1007/s13277-015-3162-3. Epub 2015 Feb 15.

PMID:
25682284
3.

The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.

Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.

Cell Biol Int. 2012 Oct 1;36(10):893-9. doi: 10.1042/CBI20110473.

PMID:
22694478
4.

[Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901].

Chen M, Xu J, Zhao J.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Feb;33(2):271-5. Chinese.

5.

Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K.

PLoS One. 2013;8(2):e56083. doi: 10.1371/journal.pone.0056083. Epub 2013 Feb 14.

6.

17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305. Epub 2008 Feb 15.

PMID:
18281615
7.

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.

Exp Hematol. 2006 Dec;34(12):1670-9.

PMID:
17157164
8.

HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.

Tavernier E, Flandrin-Gresta P, Solly F, Rigollet L, Cornillon J, Augeul-Meunier K, Stephan JL, Montmartin A, Viallet A, Guyotat D, Campos L.

J Cancer Res Clin Oncol. 2012 Oct;138(10):1753-8. Epub 2012 Jun 17.

PMID:
22706881
9.

The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.

Zhang J, Zheng Z, Zhao Y, Zhang T, Gu X, Yang W.

Clin Exp Med. 2013 Nov;13(4):323-8. doi: 10.1007/s10238-012-0208-3. Epub 2012 Sep 7.

PMID:
22955701
10.

HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio.

Mohammadi A, Yaghoobi MM, GholamhoseynianNajar A, Kalantari-Khandani B, Sharifi H, Saravani M.

Cell Mol Biol (Noisy-le-grand). 2016 Oct 31;62(12):62-67. doi: 10.14715/cmb/2016.62.12.11.

PMID:
27894402
11.

Heat Shock Protein 90 Inhibitor (17-AAG) Induces Apoptosis and Decreases Cell Migration/Motility of Keloid Fibroblasts.

Yun IS, Lee MH, Rah DK, Lew DH, Park JC, Lee WJ.

Plast Reconstr Surg. 2015 Jul;136(1):44e-53e. doi: 10.1097/PRS.0000000000001362.

PMID:
26111331
12.

Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.

J Exp Ther Oncol. 2008;7(3):183-93.

PMID:
19066127
13.

In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.

Ghadban T, Jessen A, Reeh M, Dibbern JL, Mahner S, Mueller V, Wellner UF, Güngör C, Izbicki JR, Vashist YK.

Int J Mol Med. 2016 Oct;38(4):1296-302. doi: 10.3892/ijmm.2016.2696. Epub 2016 Aug 3.

PMID:
27498942
14.
15.
16.

P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.

Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H.

Int J Oncol. 2006 Nov;29(5):1111-7.

PMID:
17016641
17.

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.

Watanabe G, Behrns KE, Kim JS, Kim RD.

Cancer Chemother Pharmacol. 2009 Aug;64(3):433-43. doi: 10.1007/s00280-008-0888-2. Epub 2008 Dec 12.

18.

The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.

Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y.

Oncol Rep. 2014 Feb;31(2):619-24. doi: 10.3892/or.2013.2899. Epub 2013 Dec 5.

PMID:
24317439
19.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
20.

Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM.

J Thorac Oncol. 2008 Oct;3(10):1089-95. doi: 10.1097/JTO.0b013e3181839693.

Supplemental Content

Support Center